Furthermore, based on multiple lines of evidence, including relief of NMO symptoms, suppression of inflammation and demyelination, as well as reduction of axonal loss and neuronal apoptosis, we demonstrated that the combination therapy of C16 plus Ang1 was an effective treatment for NMO in this model. The gene discussed is ANGPT1; the disease is neuromyelitis optica.